EVALUATION OF A HERBAL MASSAGE OIL IN PAIN MANAGEMENT
- Conditions
- Health Condition 1: null- CHRONIC PAI
- Registration Number
- CTRI/2015/02/005559
- Lead Sponsor
- AYUSH ARIHANT INDUSTRIES
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 50
EITHER SEX AGED BETWEEN 30 TO 65 YEARS
PATIENTS WITH PRIMARY BACK, KNEE AND ANY MUSCULAR PAIN
WILLING AND ABLE TO PARTICIPATE IN THE STUDY
HISTORY OF ANY TRAUMA/ FRACTURED JOINT / SURGICAL/DIAGNOSTIC INTERVENTION WITH REFERENCE TO THE AFFECTED JOINT(S).
2.GROSS DISABILITY IN PERFORMING DAILY NORMAL ROUTINE I.E. BED RIDDEN PATIENTS OR CONFINED TO A WHEELCHAIR.
3.PATIENTS WITH CO MORBIDITIES SUCH AS GOUTY ARTHRITIS, RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS.
4.PATIENTS HAVING ANY DEFORMITY OF KNEE HIP OR BACK ALTERING THE GAIT AND POSTURE OF THE PATIENT.
5.PATIENTS WITH UNCONTROLLED HYPERTENSION ( >160/100 MM OF HG).
6.PATIENTS WITH UNCONTROLLED DIABETES MELLITUS{HBA1C >9%}
7.PATIENTS WITH EVIDENCE OF MALIGNANCY.
8.PATIENTS ON PROLONGED ( > 6 WEEKS) MEDICATION WITH CORTICOSTEROIDS, ANTIDEPRESSANTS, ANTICHOLINERGICS, ETC. OR ANY OTHER DRUGS THAT MAY HAVE AN INFLUENCE ON THE OUTCOME OF THE STUDY.
9.PATIENTS WHO HAVE A PAST HISTORY OF ATRIAL FIBRILLATION, ACUTE CORONARY SYNDROME, MYOCARDIAL INFARCTION, STROKE OR SEVERE ARRHYTHMIA IN THE LAST 6 MONTHS.
10.PATIENTS WITH ANY SEVERE RENAL OR HEPATIC OR ANY OTHER DISORDER WHICH MAY INTERFERE IN THE STUDY.
11.PREGNANT / LACTATING WOMAN.
12.PATIENTS WHO ARE CURRENTLY PARTICIPATING IN ANY OTHER CLINICAL TRIAL.
13.ANY OTHER CONDITION WHICH THE PRINCIPAL INVESTIGATOR THINKS MAY JEOPARDIZE THE STUDY.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CHANGE IN PATIENTâ??S GLOBAL ASSESSMENT OF THE DISEASE ACTIVITY SCALETimepoint: AT BASELINE, 7TH DAY, 14TH DAY, 21ST DAY, 28TH DAY AND AT THE END OF FOLLOW UP AFTER 06 WEEKS
- Secondary Outcome Measures
Name Time Method SAFETY AND EFFICACY OF THE DRUG IN THE PATIENT WITH CHRONIC PAINTimepoint: AT BASELINE, 7TH DAY, 14TH DAY, 21ST DAY, 28TH DAY AND AT THE END OF FOLLOW UP AFTER 06 WEEKS